Lista de obras - Vathany Kulasingam - Dominio Público Uruguay

A patient with monoclonal gammopathy-related nephrotic syndrome revealed no electrophoretic "nephrotic pattern" or skewed free light chain ratio.

artículo científico publicado en 2017

Accuracy of testosterone concentrations in compounded testosterone products

artículo científico publicado en 2015

Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer.

artículo científico publicado en 2009

Analytical evaluation of the VITROS® 5600 Integrated System in a pediatric setting and determination of pediatric reference intervals

article

CUB and zona pellucida-like domain-containing protein 1 (CUZD1): a novel serological biomarker for ovarian cancer

artículo científico publicado en 2012

Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction? ⬇️

artículo científico publicado en 2016

Deciphering the ovarian cancer ascites fluid peptidome

artículo científico publicado en 2014

Deciphering the peptidome of urine from ovarian cancer patients and healthy controls.

artículo científico publicado en 2014

Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?

artículo científico publicado en 2015

Emerging role of clinical mass spectrometry in pathology

artículo científico publicado en 2019

Evaluation of electrochemiluminescence immunoassays for immunosuppressive drugs on the Roche cobas e411 analyzer

artículo científico publicado en 2017

False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125.

artículo científico publicado en 2013

Fascin-1 is a novel biomarker of aggressiveness in some carcinomas ⬇️

artículo científico publicado el 26 de febrero de 2013

Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.

artículo científico publicado en 2013

From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade

artículo científico

Genomic profiling for copy number changes in plasma of ovarian cancer patients - a new era for cancer diagnostics?

artículo científico publicado en 2016

Glucocorticoid receptor-mediated expression of kallikrein 10 in human breast cancer cell lines

artículo científico publicado en 2007

Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines

artículo científico publicado en 2009

Immuno-mass spectrometry: quantification of low-abundance proteins in biological fluids

artículo científico publicado en 2011

Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer

artículo científico publicado en 2010

Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies

artículo científico publicado en 2012

Major milestones in translational oncology.

artículo científico publicado en 2016

Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers

artículo científico publicado en 2008

Nipple aspirate fluid proteome of healthy females and patients with breast cancer

artículo científico

Pediatric reference intervals for 28 chemistries and immunoassays on the Roche cobas® 6000 analyzer—A CALIPER pilot study

artículo científico publicado en 2010

Platform for Establishing Interlaboratory Reproducibility of Selected Reaction Monitoring-Based Mass Spectrometry Peptide Assays

artículo científico publicado en 2010

Proteomic and Genomic Technologies for Biomarker Discovery: Where Are the Biomarkers?

article by Vathany Kulasingam & Eleftherios P. Diamandis published 2006 in Clinical Proteomics

Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets

artículo científico

Quantitative mass spectrometry-based assay development and validation: From small molecules to proteins ⬇️

artículo científico publicado el 3 de octubre de 2012

Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum

artículo científico publicado en 2013

Strategies for discovering novel cancer biomarkers through utilization of emerging technologies

artículo científico publicado en 2008

Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1

artículo científico publicado en 2013

The Use of Targeted Therapies for Precision Medicine in Oncology.

artículo científico publicado en 2016

Tissue culture-based breast cancer biomarker discovery platform

artículo científico publicado en 2008

Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics.

artículo científico publicado en 2018

Urinary adenosine excretion in type 1 diabetes

artículo científico publicado en 2017

Validating urinary measurement of beta-2-microglobulin with a Roche reagent kit designed for serum measurements

artículo científico publicado en 2012

Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer

artículo científico publicado en 2016

Lista de obras de Vathany Kulasingam

A patient with monoclonal gammopathy-related nephrotic syndrome revealed no electrophoretic "nephrotic pattern" or skewed free light chain ratio.

Accuracy of testosterone concentrations in compounded testosterone products

Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer.

Analytical evaluation of the VITROS® 5600 Integrated System in a pediatric setting and determination of pediatric reference intervals

CUB and zona pellucida-like domain-containing protein 1 (CUZD1): a novel serological biomarker for ovarian cancer

Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction? ⬇️

Deciphering the ovarian cancer ascites fluid peptidome

Deciphering the peptidome of urine from ovarian cancer patients and healthy controls.

Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?

Emerging role of clinical mass spectrometry in pathology

Evaluation of electrochemiluminescence immunoassays for immunosuppressive drugs on the Roche cobas e411 analyzer

False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125.

Fascin-1 is a novel biomarker of aggressiveness in some carcinomas ⬇️

Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.

From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade

Genomic profiling for copy number changes in plasma of ovarian cancer patients - a new era for cancer diagnostics?

Glucocorticoid receptor-mediated expression of kallikrein 10 in human breast cancer cell lines

Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines

Immuno-mass spectrometry: quantification of low-abundance proteins in biological fluids

Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer

Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies

Major milestones in translational oncology.

Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers

Nipple aspirate fluid proteome of healthy females and patients with breast cancer

Pediatric reference intervals for 28 chemistries and immunoassays on the Roche cobas® 6000 analyzer—A CALIPER pilot study

Platform for Establishing Interlaboratory Reproducibility of Selected Reaction Monitoring-Based Mass Spectrometry Peptide Assays

Proteomic and Genomic Technologies for Biomarker Discovery: Where Are the Biomarkers?

Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets

Quantitative mass spectrometry-based assay development and validation: From small molecules to proteins ⬇️

Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum

Strategies for discovering novel cancer biomarkers through utilization of emerging technologies

Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1

The Use of Targeted Therapies for Precision Medicine in Oncology.

Tissue culture-based breast cancer biomarker discovery platform

Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics.

Urinary adenosine excretion in type 1 diabetes

Validating urinary measurement of beta-2-microglobulin with a Roche reagent kit designed for serum measurements

Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer

“Product Ion Monitoring” Assay for Prostate-Specific Antigen in Serum Using a Linear Ion-Trap